Á lódáil...
Treatment of walking impairment in multiple sclerosis with dalfampridine
Potassium channel blockade has long been considered a potential therapeutic strategy for treatment of multiple sclerosis (MS) based on the pathophysiology of demyelinated axons. Dalfampridine, which is also known as fampridine or 4-aminopyridine (4-AP), is the potassium channel blocker that has been...
Na minha lista:
| Príomhúdar: | |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
SAGE Publishing
2011-03-01
|
| Sraith: | Therapeutic Advances in Neurological Disorders |
| Rochtain Ar Líne: | https://doi.org/10.1177/1756285611403960 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|